Robert J. Jones

Active 1984–2025

Also published as
Robert J Jones
113
Papers
26,127
Citations
63
h-index
103
i10-index

Citations

Citations per year for Robert J. Jones1956: 1 citations1986: 2 citations1987: 1 citations1988: 3 citations1990: 2 citations1993: 1 citations1994: 8 citations1995: 2 citations1996: 12 citations1997: 5 citations1998: 5 citations1999: 17 citations2000: 11 citations2001: 17 citations2002: 24 citations2003: 33 citations2004: 36 citations2005: 36 citations2006: 27 citations2007: 37 citations2008: 17 citations2009: 31 citations2010: 28 citations2011: 47 citations2012: 72 citations2013: 148 citations2014: 156 citations2015: 161 citations2016: 203 citations2017: 270 citations2018: 286 citations2019: 897 citations2020: 1,014 citations2021: 1,010 citations2022: 731 citations2023: 615 citations2024: 1,080 citations2025: 521 citations2026: 18 citations1957–1985: no citations, so these years are not shown1989: no citations, so this year is not shown1991–1992: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,616 citing papers, 23.9% of this breakdownUnited Kingdom: 952 citing papers, 8.7% of this breakdownChina: 732 citing papers, 6.7% of this breakdownItaly: 614 citing papers, 5.6% of this breakdownCanada: 559 citing papers, 5.1% of this breakdownGermany: 534 citing papers, 4.9% of this breakdownFrance: 534 citing papers, 4.9% of this breakdownSpain: 406 citing papers, 3.7% of this breakdownAustralia: 383 citing papers, 3.5% of this breakdownJapan: 322 citing papers, 2.9% of this breakdownNetherlands: 313 citing papers, 2.9% of this breakdownSwitzerland: 293 citing papers, 2.7% of this breakdown
0%23.9%Other 24.5%

Fields

  • Medicine72.2%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Agricultural and Biological Sciences2.8%
  • Neuroscience1.4%
  • Immunology and Microbiology1.3%
  • Health Professions0.7%
  • Other4.3%

Topics

  • Prostate Cancer Treatment and Research15.6%
  • Prostate Cancer Diagnosis and Treatment8.3%
  • PARP inhibition in cancer therapy3.7%
  • Radiopharmaceutical Chemistry and Applications3.4%
  • Renal cell carcinoma treatment3.3%
  • Cancer, Lipids, and Metabolism3%
  • Other62.7%

Coauthors

All papers

Open in search
  1. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet 2023 cited by 499

  2. Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher M. Haqq, Howard I. Scher - New England Journal of Medicine 2011 cited by 4,394

  3. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes - New England Journal of Medicine 2017 cited by 1,772

  4. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi‐Mi Wu, Xuhong Cao, Rachel Brough, Helen N. Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind A. Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono - New England Journal of Medicine 2015 cited by 2,187

  5. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar - The Lancet 2015 cited by 1,968

  6. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes - The Lancet 2018 cited by 1,262

  7. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 cited by 127

  8. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  9. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bora Gürel, Mateus Crespo, Daniel Nava Rodrigues, Shahneen Sandhu, Aude Espinasse, Peter Chatfield, Nina Tunariu, Wei Yuan, Emma Hall, Suzanne Carreira, Johann S. de Bono - The Lancet Oncology 2019 cited by 644

  10. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 1,918

  11. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey and 73 more - The Lancet 2021 cited by 367

  12. Genomics of lethal prostate cancer at diagnosis and castration resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Núria Porta, Emma Hall, Wei Yuan, Suzanne Carreira, Johann S. de Bono - Journal of Clinical Investigation 2019 cited by 304

  13. A framework for the development of effective anti-metastatic agents

    Authors: , , , , , , , , , , , , , , , , , - Nature Reviews Clinical Oncology 2018 cited by 355

  14. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2012 cited by 1,387

  15. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joanna Gale, Stephanie Gibbs, Anna Lydon, Ashok Nikapota, Aurelius Omlin, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Sarah Rudman, Narayanan Srihari, Matthew Simms, Jacob Tanguay, Shaun Tolan, John Wagstaff, Jan Wallace, J. Wylie, Anjali Zarkar, Matthew R. Sydes, Mahesh Parmar, Nicholas D. James - Annals of Oncology 2019 cited by 398

  16. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 cited by 527

  17. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan C. Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise Brown, Mahesh Parmar, Nicholas D. James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, D. Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, M. Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan B. McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry M. Taylor, John D. Graham and 80 more - The Lancet Oncology 2023 cited by 102

  18. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118

  19. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 cited by 424

  20. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Daniel Ford, Joanna Gale, Ann Henry, Peter Hoskin, M. Kagzi, Anna Lydon, Joe M. O’Sullivan, Sangeeta Paisey, Omi Parikh, Delia Pudney, Vijay Ramani, Peter Robson, Narayanan Srihari, Jacob Tanguay, Mahesh Parmar, Matthew R. Sydes, for the STAMPEDE Trial Collaborative Group - PLoS Medicine 2022 cited by 121

  21. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Judith Carser, Gopalakrishnan Srinivasan, Fiona Thistlewaite, Ashraf Azzabi, Mark Beresford, David Farrugia, M. Decatris, Carys Thomas, Joanna Gale, James J McAleer, Alison Clayton, Ekaterini Boleti, T. Geldart, Santhanam Sundar, J.F. Lester, Nachi Palaniappan, Mohan Hingorani, Khaliq Rehman, Mohammad Adil Khan, Naveed Sarwar, Janine Graham, Alastair Thomson, Narayanan Srihari, Denise Sheehan, R. Srinivasan, Omar Khan, Andrew Stockdale Jane Worlding, Stergios Boussios, N Stuart, Carey MacDonald-Smith, Falalu Danwata, Duncan McLaren, Aravindhan Sundaramurthy, Anna Lydon, S. Beesley, Kathryn Lees, Mohini Varughese, Emma Gray, Angela Scott, Mark Baxter, Anna Mullard, Pasquale F. Innominato, Gaurav Kapur, Anil Kumar, Natalie Charnley, Caroline Manetta, Prabir Chakraborti, Prantik Das, Sarah Rudman, Henry F. Taylor, Christos Mikropoulos, Martin Highley, D. Muthukumar, Anjali Zarkar, Roy Vergis, Seshadri Sriprasad, Patryk Brulinski, Amanda Clarke, Richard Osbourne, Melanie Harvey, Renata Dega, Geoffrey Sparrow, U. Barthakur, Erica Beaumont, Caroline Manetta, Agnieszka Michael, Emilio Porfiri, Faisal Azam, Ravi Kodavtiganti - The Lancet Oncology 2023 cited by 81

  22. Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Prantik Das, Dan Ford, Joanna Gale, Warren Grant, Emma Gray, Peter Hoskin, Mohammad Muneeb Khan, Caroline Manetta, Neil McPhail, Joe M. O’Sullivan, Omi Parikh, Carla Perna, Carmel Pezaro, Andrew Protheroe, Angus Robinson, Sarah Maria Rudman, D.J. Sheehan, Narayanan Srihari, Isabel Syndikus, Jacob Tanguay, Carys Thomas, Salil Vengalil, John Wagstaff, James Wylie, Mahesh Parmar, Matthew R. Sydes, for the STAMPEDE Trials Collaborative Group - International Journal of Cancer 2022 cited by 77

  23. Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 81

  24. Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2019 cited by 205